Wissenschaftliche Arbeiten

Doç. Dr. Nargız Majıdova

92 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

    Medicina, 2026

    DOI 10.3390/medicina62050984 PMID 42195237 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-04842-3 PMID 41870760 Frei zugänglicher VolltextQuelle: OpenAlex

  3. Which patients with colorectal cancer develop brain metastases? A multicenter analysis of clinical and molecular predictors.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.2_suppl.218 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Clinicopathologic and molecular characteristics of colorectal cancer patients with brain metastases: a multicenter cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-69206-x Frei zugänglicher VolltextQuelle: OpenAlex

  5. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  6. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Therapeutic Advances in Medical Oncology, 2026

    DOI 10.1177/17588359261430583 PMID 41835339 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  7. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Quelle: OpenAlex

  8. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Quelle: OpenAlex

  9. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33060365 PMID 42346265 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort

    Medicina, 2026

    DOI 10.3390/medicina62081601 PMID 42654498 Frei zugänglicher VolltextQuelle: OpenAlex

  11. Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study

    The Breast, 2026

    DOI 10.1016/j.breast.2026.104936 PMID 42777557 Frei zugänglicher VolltextQuelle: ORCID

  12. Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15134901 PMID 42452362 Frei zugänglicher VolltextQuelle: ORCID

  13. Multicenter Real‐World Evaluation of Neoadjuvant Carboplatin in Triple‐Negative Breast Cancer

    Cancer Medicine, 2026

    DOI 10.1002/cam4.71951 PMID 42163828 Frei zugänglicher VolltextQuelle: ORCID

  14. Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041554 PMID 41753241 Frei zugänglicher VolltextQuelle: ORCID

  15. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020642 PMID 41598581 Frei zugänglicher VolltextQuelle: ORCID

  16. Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020798 PMID 41598735 Frei zugänglicher VolltextQuelle: ORCID

  17. Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020890 PMID 41598826 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  18. Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

    Medicina, 2026

    DOI 10.3390/medicina62010098 PMID 41597384 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  19. Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2026

    DOI 10.1016/j.clbc.2025.11.014 PMID 41456513 Quelle: ORCID

  20. Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

    Scientific reports, 2026

    DOI 10.1038/s41598-026-50526-x PMID 42103792 Frei zugänglicher VolltextQuelle: Europe PMC

  21. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

    Discover oncology, 2026

    DOI 10.1007/s12672-026-04705-x PMID 41721952 Frei zugänglicher VolltextQuelle: Europe PMC

  22. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

    Scientific reports, 2026

    DOI 10.1038/s41598-026-48955-9 PMID 41981174 Frei zugänglicher VolltextQuelle: Europe PMC

  23. Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer

    Expert review of anticancer therapy, 2026

    DOI 10.1080/14737140.2026.2615853 PMID 41511755 2 Zitationen (Europe PMC) Quelle: ORCID

  24. Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16667-y PMID 42693417 Frei zugänglicher VolltextQuelle: OpenAlex

  25. Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure

    The Breast, 2026

    DOI 10.1016/j.breast.2026.104785 PMID 41980521 Frei zugänglicher VolltextQuelle: OpenAlex

  26. Digital health engagement and health literacy among cancer patients: a cross-sectional study of ICT usage patterns

    BMC Health Services Research, 2026

    DOI 10.1186/s12913-026-15432-y 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  27. Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group

    Frontiers in Oncology, 2026

    DOI 10.3389/fonc.2026.1756315 PMID 42482752 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  28. Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-04859-8 PMID 42014558 Frei zugänglicher VolltextQuelle: OpenAlex

  29. Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14062024 PMID 40142832 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  30. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 Zitationen (Europe PMC) Quelle: OpenAlex

  31. Efficacy of anti-VEGF & anti-EGFRs in microsatellite instable (MSI-H) metastatic colorectal cancer, Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e15507 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  32. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

    Current Oncology, 2025

    DOI 10.3390/curroncol32110639 PMID 41294701 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  33. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61030490 PMID 40142301 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  34. Kanserde Takip

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716 Frei zugänglicher VolltextQuelle: OpenAlex

  35. Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer

    Breast Cancer Research and Treatment, 2025

    DOI 10.1007/s10549-025-07694-7 PMID 40214840 2 Zitationen (Europe PMC) Quelle: OpenAlex

  36. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  37. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-96157-6 PMID 40188172 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  38. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14134568 PMID 40648939 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  39. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-87553-z PMID 39863702 Frei zugänglicher VolltextQuelle: OpenAlex

  40. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors

    Cancers, 2025

    DOI 10.3390/cancers17040693 PMID 40002286 14 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  41. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14041071 PMID 40004601 9 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  42. Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14124189 PMID 40565933 Frei zugänglicher VolltextQuelle: ORCID

  43. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

    Journal of Chemotherapy, 2025

    DOI 10.1080/1120009x.2024.2430845 PMID 39588941 1 Zitation (Europe PMC) Quelle: ORCID

  44. Efficacy of Subsequent Therapy in Patients with Hormone-Positive Advanced Breast Cancer with Disease Progression After CDK4/6 Inhibitor Therapy: Multicenter Real-Life Data

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14207376 PMID 41156245 Frei zugänglicher VolltextQuelle: ORCID

  45. Yumuşak Doku Sarkomları

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716.c6083 Quelle: ORCID

  46. The Role of Baseline PET/CT Parameters in Predicting Treatment Response in Patients with Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy

    Medicina, 2025

    DOI 10.3390/medicina61081449 PMID 40870493 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  47. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

    Turkish Journal of Gastroenterology, 2025

    DOI 10.5152/tjg.2025.24784 PMID 40241388 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  48. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1575691 Frei zugänglicher VolltextQuelle: ORCID

  49. Lung Immune Prognostic Index (LIPI): Prognostic predictor for patients with extensive-stage small-cell lung cancer

    Marmara Medical Journal, 2025

    DOI 10.5472/marumj.1627671 Frei zugänglicher VolltextQuelle: ORCID

  50. Oncological perspective on Kaposi sarcoma: A single-centre experience

    Marmara Medical Journal, 2025

    DOI 10.5472/marumj.1627569 Frei zugänglicher VolltextQuelle: ORCID